Vertex CEO takes Morgan Stanley analyst to task at conference

Vertex Pharmaceuticals ($VRTX) CEO Matthew Emmens didn't stick with the script at yesterday's Morgan Stanley Global Healthcare Conference. Armed with stellar early sales figures for Vertex's new hep C drug Incivek, Emmens scolded the investment bank's own analyst David Friedman, accusing him of failing to understand the company. Report

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.